HomeCompareSAKL vs JNJ

SAKL vs JNJ: Dividend Comparison 2026

SAKL yields 25000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SAKL wins by $481652020747103174656.00M in total portfolio value
10 years
SAKL
SAKL
● Live price
25000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$481652020747103174656.00M
Annual income
$477,891,679,681,809,340,000,000,000.00
Full SAKL calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SAKL vs JNJ

📍 SAKL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSAKLJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SAKL + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SAKL pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SAKL
Annual income on $10K today (after 15% tax)
$2,125,000.00/yr
After 10yr DRIP, annual income (after tax)
$406,207,927,729,537,960,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SAKL beats the other by $406,207,927,729,537,960,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SAKL + JNJ for your $10,000?

SAKL: 50%JNJ: 50%
100% JNJ50/50100% SAKL
Portfolio after 10yr
$240826010373551587328.00M
Annual income
$238,945,839,840,904,670,000,000,000.00/yr
Blended yield
99.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SAKL
No analyst data
Altman Z
-41.7
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SAKL buys
0
JNJ buys
0
No recent congressional trades found for SAKL or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSAKLJNJ
Forward yield25000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$481652020747103174656.00M$30.3K
Annual income after 10y$477,891,679,681,809,340,000,000,000.00$4,689.40
Total dividends collected$481404327977371041792.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SAKL vs JNJ ($10,000, DRIP)

YearSAKL PortfolioSAKL Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$2,510,700$2,500,000.00$10,592$272.30+$2.50MSAKL
2$589,298,599$586,612,149.53$11,289$357.73+$589.29MSAKL
3$129,309,604,119$128,679,054,618.90$12,123$472.89+$129309.59MSAKL
4$26,527,150,102,459$26,388,788,826,051.22$13,141$629.86+$26527150.09MSAKL
5$5,087,743,001,217,608$5,059,358,950,607,977.00$14,408$846.81+$5087743001.20MSAKL
6$912,316,496,169,531,500$906,872,611,158,228,600.00$16,021$1,151.60+$912316496169.52MSAKL
7$152,954,929,371,424,950,000$151,978,750,720,523,570,000.00$18,122$1,588.22+$152954929371424.91MSAKL
8$23,976,822,470,935,107,000,000$23,813,160,696,507,682,000,000.00$20,930$2,228.20+$23976822470935108.00MSAKL
9$3,514,337,444,199,857,700,000,000$3,488,682,244,155,957,000,000,000.00$24,792$3,191.91+$3514337444199857664.00MSAKL
10$481,652,020,747,103,200,000,000,000$477,891,679,681,809,340,000,000,000.00$30,274$4,689.40+$481652020747103174656.00MSAKL

SAKL vs JNJ: Complete Analysis 2026

SAKLStock

Sack Lunch Productions, Inc., together with its subsidiaries, engages in the event and film production businesses worldwide. The company operates through three segments: Events, Salons, and Other. The Events segment produces branded events under the Color Me Rad, The Dirty Dash, Lantern Fest, Slide the City, and Trike Riot trademarked names; and franchises its branded events to third parties under agreements with various franchisees. The Salons segment operates health and beauty salons. This segment operates through a network of two Aveda lifestyle salons; and an Aveda retail store. The Other segment distributes films; provides assisting services in the development and production of film products; and acquires, leases, and sells commercial and residential properties. The company was formerly known as Nexia Holdings, Inc. and changed its name to Sack Lunch Productions, Inc. in April 2015. Sack Lunch Productions, Inc. was incorporated in 1987 and is headquartered in Salt Lake City, Utah.

Full SAKL Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SAKL vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SAKL vs SCHDSAKL vs JEPISAKL vs OSAKL vs KOSAKL vs MAINSAKL vs ABBVSAKL vs MRKSAKL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.